152218-31-0

Upstream product

• 121-73-3 3-Nitrochlorobenzene 
• 513-42-8 3-hydroxy-2-methyl-1-propene 
• 86884-89-1 (R)-2-methylglycidol 
• 121-51-7 3-nitrobenzenesulphonyl chloride 

Downstream Products

• 644968-88-7 4-(acetylamino)-3-{[(2S)-2-methyloxiran-2-yl]methoxy}phenyl benzoate 
• 644969-13-1 N-cyclopropyl-4-[(4-methoxybenzyl)oxy]-2-{[(2S)-2-methyloxiran-2-yl]methoxy}benzamide 
• 924663-84-3 N-(5-chloro-4-methoxy-2-{[(2S)-methyloxiran-2-yl]methoxy}phenyl)propanamide 
• 936328-06-2 methyl 3-(2-{[(2S)-2-methyloxiran-2-yl]methoxy}phenyl)propanoate 
• 936327-85-4 methyl (2-{[(2S)-2-methyloxiran-2-yl]methoxy}phenyl)acetate 
• 936329-23-6 methyl {4-fluoro-2-[(2S)-2-methyl-oxiran-2-ylmethoxy]phenyl}acetate 
• 936328-22-2 methyl (2E)-3-(5-fluoro-2-{[(2S)-2-methyloxiran-2-yl]methoxy}phenyl)acrylate 
• 936327-97-8 methyl 3-(4-fluoro-2-{[(2S)-2-methyloxiran-2-yl]methoxy}phenyl)propanoate 
• 936329-50-9 (2-{[(2S)-2-methyloxiran-2-yl]methoxy}phenyl)acetonitrile 

Relevant academic research and scientific papers

Pyrimidinedione derivative capable of inhibiting monocarboxylate transporter

The invention relates to a pyrimidinedione derivative capable of inhibiting a monocarboxylate transporter, the pyrimidinedione derivative is a formula (I) compound and/or a pharmaceutically acceptablesalt thereof, and/or a stereoisomer thereof, and/or a solvate thereof, the compound has the effect of inhibiting the activity of the monocarboxylate transporter, and also comprises a pharmaceutical composition containing the formula (I) compound and the use of the pharmaceutical composition in treatment.

CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS

The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

Development of a multikilogram synthesis of a chiral epoxide precursor to a CCR1 antagonist. Use of in situ monitoring for informed optimisation via fragile intermediates

The optimisation and scale up of a manufacturing route to a key intermediate, acetic acid 4-acetylamino-3-(2-methyl-oxiranyl- methoxy)phenyl ester (2), utilising a SNAr coupling, the hydro- genation of a nitro moiety and the conversion of a chi

NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Novel compounds

The invention provides compounds of general formula (I) wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Bispidine antiarrhythmic compounds

There is provided a compound of formula I, wherein R1, R2, R9, R10, R11, R12, X, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.